Description

Beta Drugs Limited's equity shares listed on NSE Capital Market Segment (Main Board) following migration from SME Emerge platform, effective November 13, 2025.

Summary

Beta Drugs Limited (NSE Symbol: BETA, ISIN: INE351Y01019) has been listed on NSE’s Capital Market Segment (Main Board) following its migration from the SME Emerge platform. The listing became effective on November 13, 2025. The company filed its quarterly shareholding pattern under Regulation 31(1)(b) as of the listing date.

Key Points

  • Company Name: Beta Drugs Limited
  • NSE Symbol: BETA
  • ISIN: INE351Y01019
  • Listing Date: November 13, 2025
  • Migration: From SME Emerge platform to Main Board
  • Security Type: Equity Shares
  • Total Shares Outstanding: 10,094,553 shares (fully diluted basis)
  • Total Shares in Dematerialized Form: 10,094,553 shares (100%)
  • Public Sector Undertaking: No

Shareholding Structure

As of November 13, 2025:

  • Promoter and Promoter Group: 6,736,507 shares (66.73%)
  • Public Shareholders: 3,358,046 shares (33.27%)
  • Non Promoter-Non Public: 0 shares (0.00%)

Voting Rights Distribution:

  • Promoter Group: 6,736,507 voting rights (66.73%)
  • Public Shareholders: 3,358,046 voting rights (33.27%)

Capital Structure Details

  • No partly paid-up shares issued
  • No convertible securities outstanding
  • No warrants issued
  • No outstanding ESOPs
  • No depository receipts against shares
  • No shares in locked-in status
  • No promoter shares pledged or under Non-Disposal Undertaking
  • No promoter shares encumbered
  • No equity shares with differential voting rights
  • No significant beneficial owners reported
  • All shares held in dematerialized form (100%)

Regulatory Changes

The migration from SME Emerge platform to Main Board represents a graduation for Beta Drugs Limited, subjecting the company to Main Board listing requirements and compliance standards under SEBI regulations and NSE listing rules.

Compliance Requirements

  • Quarterly shareholding pattern filing under Regulation 31(1)(b)
  • Adherence to Main Board listing agreement requirements
  • Enhanced disclosure and corporate governance standards applicable to Main Board listed companies
  • Compliance with minimum public shareholding norms (currently at 33.27%)

Important Dates

  • November 13, 2025: Listing date on Capital Market Segment (Main Board)
  • November 13, 2025: Quarter ended date for shareholding pattern filing

Impact Assessment

Market Impact:

  • Enhanced liquidity potential due to Main Board listing
  • Broader investor base accessibility
  • Improved visibility and credibility for the company
  • Higher trading volumes expected compared to SME platform

Operational Impact:

  • Increased regulatory compliance requirements
  • Higher disclosure standards and transparency obligations
  • Enhanced corporate governance framework
  • Greater scrutiny from institutional investors and analysts

Investor Impact:

  • Better price discovery mechanism on Main Board
  • Access to wider pool of institutional and retail investors
  • Improved market depth and trading infrastructure
  • Enhanced exit opportunities for existing shareholders

Impact Justification

Significant corporate action involving migration from SME to Main Board, affecting trading and investor participation for Beta Drugs Limited